Investor's Business Daily • yesterday
Neurocrine's Tourette drug failed in a trial and the FDA approved a generic narcolepsy drug rivaling Jazz, and both stocks fell late.
TheStreet.com • 2 days ago
The same Neurocrine drug, valbenazine, is currently under review at the FDA as a treatment for the movement disorder tardive dyskinesia.
Insider Monkey • 2 days ago
The biotechnology sector is in full swing for the New Year, and while the JP Morgan conference is now in the rearview mirror, there are still plenty of potential catalysts set to hit press between now and the end of January. Here are two of the releases that we are most highly anticipating, with a […]
Capital Cube • 8 days ago
Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Neurocrine Biosciences, Inc. a score of 29. Our analysis is based on comparing Neurocrine Biosciences, Inc. with the following peers – Repligen Corporation, Repros Therapeutics Inc., Paratek Pharmaceuticals Inc, Palatin Technologies, Inc., Pfizer Inc., Eli Lilly and Company, AbbVie, Inc., CASI Pharmaceuticals Inc, ANI Pharmaceuticals, Inc. and ... Read more (Read more...)
Capital Cube • 9 days agoNeurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : January 10, 2017
Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Neurocrine Biosciences, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more (Read more...)
Zacks Small Cap Research • 13 days ago
On January 5, 2017, Neurocrine Biosciences, Inc. (NBIX) announced that the Food and Drug Administration (FDA) has cancelled the Psychopharmacologic Drugs Advisory Committee meeting that was originally scheduled for Feb. 16, 2017 after further review of the INGREZZA™ New Drug Application (NDA). The FDA informed the company that the Priority Review of the NDA for INGREZZA™ for the treatment of tardive dyskinesia (TD) was continuing as planned with the previously announced Prescription Drug User Fee Act (PDUFA) date of April 11, 2017. During the conference call to discuss the situation, management indicated that they have had nothing but positive interactions with the FDA up to and during review of the NDA and that they were not aware of any issues with the review of the NDA.
Insider Monkey • 13 days ago
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) just announced that that the FDA has cancelled the Psychopharmacologic Drugs Advisory Committee meeting for INGREZZA. The meeting, which was originally scheduled to take place on February 16, 2017, will now be skipped, and the drug will carry straight through to the PDUFA date, scheduled for April 11, 2017. This is […]
24/7 Wall St. • 13 days ago
A new Jefferies research report makes the case that five top biotech companies may be right in the cross-hairs of the biotech giants or perhaps large pharmaceutical companies.
NBIX : Summary for Neurocrine Biosciences, Inc. - Yahoo Finance
Neurocrine Biosciences, Inc. (NBIX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||31.59 x 100|
|Day's Range||38.84 - 43.44|
|52 Week Range||31.25 - 55.15|
|PE Ratio (TTM)||-28.93|
|Earnings Date||Feb 9, 2017 - Feb 13, 2017|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||66.92|